by Raynovich Rod | Nov 14, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Red Tape Today Means Caution-Take Some Off XBI at $167.83 Off 2% Traders, investors, executives even pension funds are thrilled with biotech investing as the stock group rolls on to new highs this month. What may not be appreciated is the 20% move off the October 16...
by Raynovich Rod | Oct 31, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from...
by Raynovich Rod | Oct 13, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
10/14 …Update 3:10p Here come the sellers late in the day on schedule. Investors are trying to hold the fort. Oil down, treasuries up, JPMorgan misses off 0.43%. XLE off 0.57%, Gold steady at 1233, biotechs mixed but GILD down 5%, industrials and technology in...
by Raynovich Rod | Oct 6, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ Slides After Good Opening -Down 0.47% The enthusiasm generated by Friday’s jobs report waned after the opening. The shocking 92% decline in shares of GT Advanced Technologies , Inc.(GTAT) due to a bankruptcy filing rattled traders and drove small cap...
by Raynovich Rod | Oct 1, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
10/3 Jobs Report Clears Path for Q4 Rally 3:30P EDT A more optimistic view of the economy was triggered by a steady gain in jobs with 248k added in August and unemployment dropping below 6% to 5.9%. But average hourly wages fell in September keeping wage growth...
by Raynovich Rod | Sep 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Update -1 Choppy Market Continues..Faux Rally on Wednesday? NASDAQ at 4561 Down 0.66% 1-Reiterate profit taking in Achillion (ACHN), Exact Sciences (EXAS) and Illumina (ILMN). 2-XBI treading water at 160 since August 26. Bull market intact. 3-Recent early August new...
by Raynovich Rod | Sep 5, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1 …Market Continues Sell-Off With QQQs Treading Water in September Follow Technicals on FBT and QQQ. The Federal Reserve continues to be the main concern of investors as the probability of a rate hike looms greater and sooner. Policy officials will meet...
by Raynovich Rod | Aug 26, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Stocks- Including New Picks Another great day for biotech with most Rayno stocks in a rally mode with a bit of profit taking on Gilead Sciences(GILD) down 1%. Notable movers up on our core picks are: Alkermes (ALKS), Amgen (AMGN), Ariad (ARIA),...
by Raynovich Rod | Aug 25, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Look for a decent rally in the biotech sector today after Roche agreed to pay $8.3B for Intermune which is awaiting approval of pirfenidone,a treatment for idiopathic pulmonary fibrosis. The stock is up 36% in pre-market today and was already up 17% over one month....
by Raynovich Rod | Aug 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Life Science ETF's and Mutual Funds
Large Caps Rule Macro and Seasonal Risks Create a Choppy Market The August biotech rally has taken us to the midpoint of the February top and May bottom and is faltering. Look at the XBI SPDR S&P biotech ETF (XBI), a proxy for momentum and smaller cap trading, up...
